Photo Release -- OraSure Technologies Receives Popular Science "Best of What's New" Award for OraQuick(R) HCV Rapid Antibody Tes
17 11월 2010 - 8:00PM
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral
fluid diagnostics, today announced that the editors of Popular
Science have named the OraQuick® HCV Rapid Antibody Test one of the
top technology innovations of 2010. As a winner of a "Best of
What's New" Award, the OraQuick HCV Rapid Antibody Test was
recognized for its technology and being the first ever rapid,
point-of-care test approved by the FDA for the detection of
antibodies to the HCV (hepatitis C) virus.
A photo accompanying this release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8335
"We are honored to be recognized by Popular Science magazine as
an innovative company that is making revolutionary strides to help
identify more at risk individuals infected with hepatitis C," said
Douglas A. Michels, President and Chief Executive Officer of
OraSure Technologies. "This award is a reflection of the passion
and commitment of our employees, partners and customers in the
fight against hepatitis C."
Each year, the editors of Popular Science review thousands of
products in search of the top 100 tech innovations of the year;
breakthrough products and technologies that represent a significant
leap in their categories. The winners – the Best of What's New –
are awarded inclusion in the December issue of Popular Science, the
most widely read issue of the year.
"For 23 years, Popular Science has honored the innovations that
surprise and amaze us − those that make a positive impact on our
world today and challenge our views of what's possible in the
future," said Mark Jannot, Editor-in-Chief of Popular Science. "The
Best of What's New Award is the magazine's top honor, and the 100
winners – chosen from among thousands of entrants – represent the
highest level of achievement in their fields. We congratulate
OraSure and its employees on this accomplishment."
The OraQuick HCV test was approved in June of this year by the
FDA for use with venous whole blood specimens. Following
approval, the Company submitted in July an additional application
to the FDA for approval with a fingerstick blood sample using the
OraQuick HCV test.
As previously announced, OraSure entered into agreements with
Merck & Co. (through its predecessor Schering Plough
Corporation) to collaborate on the development and promotion of the
OraQuick® HCV test. Under the terms of these agreements, the
Company has been and will be reimbursed by Merck for a portion of
its costs to develop the test and obtain regulatory approvals.
Additionally, Merck will provide promotional support, including
detailing the test in the physicians' office market in those
countries in which the Company has obtained approval.
In the U.S., there are an estimated 4.1 million Americans, or
1.6 percent of the population, that are or have been infected with
HCV. On a worldwide basis, there are an estimated 180 million
people who are chronically infected with HCV, with an estimated 3
to 4 million individuals newly infected each year. According
to the World Health Organization, most cases of HCV infection are
currently undiagnosed and up to 80 percent of HCV-positive
individuals show no signs or symptoms.
About Popular Science Founded in 1872, Popular
Science (www.popsci.com) is the world's largest science and
technology magazine, with a circulation of 1.3 million and 7.1
million readers. Each month, Popular Science delivers "The Future
Now," reporting on the intersection of science and everyday life
with an eye toward what's new and why it matters. Popular Science
is published by the Bonnier Corporation (www.bonniercorp.com), one
of the largest consumer publishing groups in America and the
leading media company serving passionate, highly engaged audiences
through more than 40 special-interest magazines and related
multimedia projects and events.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral
fluid specimen collection devices using proprietary oral fluid
technologies, diagnostic products including immunoassays and other
in vitro diagnostic tests, and other medical devices. These
products are sold in the United States as well as internationally
to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities.
For more information on the Company, please go to
www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: Zer0 to 5ive
Media Contact:
Michael Levey
610-223-2632
Michael@0to5.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024